Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-24T07:22:53.681Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical experience with the new double aripiprazole depot regime in a psychiatric hospitalization unit

Published online by Cambridge University Press:  01 September 2022

Á. Moleón Ruiz ,
R. Tenorio Villegas  and
A. Gómez Rebollo
Á. Moleón Ruiz
Affiliation:
Hospital Juan Ramón Jiménez, Psychiatry, Huelva, Spain
R. Tenorio Villegas*
Affiliation:
Hospital Juan Ramón Jiménez, Psychiatry, Huelva, Spain
A. Gómez Rebollo
Affiliation:
Hospital Juan Ramón Jiménez, Psychiatry, Huelva, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Nowadays, relapses are typical in patients with schizophrenia and may have serious implications due to most of them are caused by a lack of adherence to treatment.Therefore, numerous long-acting injectable antipsychotics (LAI) have been developed as aripiprazole depot who need a proper oral supplementation. Since November 2020, FDA approved a new treatment indication with a double injection start and a single dose of 20mg of oral aripiprazole, with the aim of avoiding oral supplementation during the next 14 days.

Objectives

The purpose of our study is to expose our experience with the new double injection start with aripiprazole LAI, regarding the rehospitalization rate.

Methods

A prospective study (n=17 patients) has been developed between November 2020 and October 2021 with the purpose of studying the rehospitalization and antipsychotic adherence after the new guideline of aripiprazole

Results

After an 11-month-follow-up, it is noticed a 65% non-rehospitalization rate and a 76% proper treatment persistence rate. The 94% did not present any kind of side effects, only one patient had a case report of bullous pemphigoid. Regarding the concomitant use of other antipsychotics, 82% of the patients remained in monotherapia. The average stay time was shortened (11 days) regarding the standard dose (14 days).

Conclusions

The new LAI regimen is well tolerated in our patients obtaining a high treatment persistence after several months of hospital discharge. It was already possible to shorten the time of rehospitalization, not having to add oral aripiprazole for 14 days. Most patients were discharged are on antipsychotic monotherapy and have not been rehospitalized in the short term.

Disclosure

No significant relationships.

Keywords

relapseschizophreniaaripiprazoleLAI
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S729
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.